Autotaxin impedes anti-tumor immunity by suppressing chemotaxis and tumor infiltration of CD8+ T cells
Elisa Matas-Rico,
Elselien Frijlink,
Irene van der Haar Àvila,
Apostolos Menegakis,
Maaike van Zon,
Andrew J. Morris,
Jan Koster,
Fernando Salgado-Polo,
Sander de Kivit,
Telma Lança,
Antonio Mazzocca,
Zoë Johnson,
John Haanen,
Ton N. Schumacher,
Anastassis Perrakis,
Inge Verbrugge,
Joost H. van den Berg,
Jannie Borst,
Wouter H. Moolenaar
Affiliations
Elisa Matas-Rico
Division of Biochemistry, Netherlands Cancer Institute, Amsterdam, the Netherlands; Corresponding author
Elselien Frijlink
Division of Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands
Irene van der Haar Àvila
Division of Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands
Apostolos Menegakis
Oncode Institute, Utrecht, the Netherlands; Division of Cell Biology, Netherlands Cancer Institute, Amsterdam, the Netherlands
Maaike van Zon
Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands
Andrew J. Morris
Division of Cardiovascular Medicine, Gill Heart Institute and Lexington Veterans Affairs Medical Center, University of Kentucky, Lexington, KY, USA
Jan Koster
Laboratory for Experimental Oncology and Radiobiology, Amsterdam UMC, Amsterdam, the Netherlands
Fernando Salgado-Polo
Division of Biochemistry, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands
Sander de Kivit
Division of Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands
Telma Lança
Oncode Institute, Utrecht, the Netherlands; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands
Antonio Mazzocca
Interdisciplinary Department of Medicine, University of Bari School of Medicine, Bari, Italy
Zoë Johnson
iOnctura SA, Campus Biotech Innovation Park, Geneva, Switzerland
John Haanen
Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands
Ton N. Schumacher
Oncode Institute, Utrecht, the Netherlands; Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands
Anastassis Perrakis
Division of Biochemistry, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands
Inge Verbrugge
Division of Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands
Joost H. van den Berg
Division of Molecular Oncology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands
Jannie Borst
Division of Tumor Biology and Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands; Oncode Institute, Utrecht, the Netherlands; Corresponding author
Wouter H. Moolenaar
Division of Biochemistry, Netherlands Cancer Institute, Amsterdam, the Netherlands; Corresponding author
Summary: Autotaxin (ATX; ENPP2) produces lysophosphatidic acid (LPA) that regulates multiple biological functions via cognate G protein-coupled receptors LPAR1-6. ATX/LPA promotes tumor cell migration and metastasis via LPAR1 and T cell motility via LPAR2, yet its actions in the tumor immune microenvironment remain unclear. Here, we show that ATX secreted by melanoma cells is chemorepulsive for tumor-infiltrating lymphocytes (TILs) and circulating CD8+ T cells ex vivo, with ATX functioning as an LPA-producing chaperone. Mechanistically, T cell repulsion predominantly involves Gα12/13-coupled LPAR6. Upon anti-cancer vaccination of tumor-bearing mice, ATX does not affect the induction of systemic T cell responses but, importantly, suppresses tumor infiltration of cytotoxic CD8+ T cells and thereby impairs tumor regression. Moreover, single-cell data from melanoma tumors are consistent with intratumoral ATX acting as a T cell repellent. These findings highlight an unexpected role for the pro-metastatic ATX-LPAR axis in suppressing CD8+ T cell infiltration to impede anti-tumor immunity, suggesting new therapeutic opportunities.